BZ trades 58.5% below Wall Street's consensus target of $21.71.
Last 12 months price action with 12-month analyst target path
The base valuation assumes BZ achieves its forward estimates and maintains a stable P/E multiple of 1.6x. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 22, 2026, Kanzhun Limited (BZ) has a Wall Street consensus price target of $21.71, based on estimates from 9 covering analysts. With the stock currently trading at $13.70, this represents a potential upside of +58.5%. The company has a market capitalization of $6.27B.
Analyst price targets range from a low of $15.00 to a high of $28.00, representing a 60% spread in expectations. The median target of $22.75 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 9 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, BZ trades at a trailing P/E of 16.2x and forward P/E of 1.6x. Analysts expect EPS to grow +49.5% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $84.85, with bear and bull scenarios of $53.46 and $111.80 respectively. Model confidence stands at 47/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
RCUSArcus Biosciences, Inc. | $2.4B | $24.31 | $31.00 | +27.5% | Buy | — | 18 |
DHXDHI Group, Inc. | $164M | $3.80 | $3.00 | -21.1% | Hold | 21.1x | 11 |
MANManpowerGroup Inc. | $1.6B | $33.55 | $37.86 | +12.8% | Hold | 9.1x | 29 |
ZMZoom Communications, Inc. | $25.3B | $86.36 | $118.50 | +37.2% | Hold | 14.3x | 49 |
UPWKUpwork Inc. | $994M | $8.05 | $14.75 | +83.2% | Buy | 5.2x | 23 |
FVRRFiverr International Ltd. | $373M | $10.38 | $16.83 | +62.1% | Hold | 5.1x | 17 |
TASKTaskUs, Inc. | $443M | $4.91 | $10.50 | +113.8% | Buy | 3.7x | 11 |
RELYRemitly Global, Inc. | $4.4B | $21.10 | $23.50 | +11.4% | Buy | 32.9x | 13 |
BIDUBaidu, Inc. | $38.0B | $111.76 | $160.29 | +43.4% | Buy | 2.1x | 53 |
BABAAlibaba Group Holding Limited | $249.8B | $107.06 | $189.17 | +76.7% | Buy | 2.4x | 59 |
Quick answers to the most common questions about buying BZ stock.
The consensus Wall Street price target for BZ is $21.71, representing 58.5% upside from the current price of $13.7. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
BZ has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is predominantly bullish, with 9 Buy/Strong Buy ratings. The consensus 12-month price target of $21.71 implies 58.5% upside from current levels.
With a forward P/E of 1.6018x, BZ trades at a relatively low valuation. The consensus target of $21.71 implies 58.5% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $28 for BZ, while the most conservative target is $15. The consensus of $21.71 represents the median expectation. Our quantitative valuation model projects a bull case target of $112 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
BZ is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 9 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month BZ stock forecast based on 9 Wall Street analysts shows a consensus price target of $21.71, with estimates ranging from $15 (bear case) to $28 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $85, with bear/bull scenarios of $53/$112.
Our quantitative valuation model calculates BZ's fair value at $85 (base case), with a bear case of $53 and bull case of $112. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 47/100.
BZ trades at a forward P/E ratio of 1.6x based on next-twelve-months earnings estimates compared to a trailing P/E of 16.2x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on BZ, with a "Buy" consensus rating and $21.71 price target (58.5% upside). 9 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
BZ analyst price targets range from $15 to $28, a 60% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $21.71 consensus represents the middle ground. Our model's $53-$112 range provides an independent fundamental perspective.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.